Dulaglutide versus empagliflozin as add-on therapy to metformin and sulfonylurea in type 2 diabetes: a randomized pilot study with exploratory metabolomic and microbiome analyses
Ji Eun Jun, Da-Hee Oh, In-Kyung Jeong, Hyun Jin Ryu, You-Cheol Hwang, Kyu Jeung Ahn, Ho Yeon Chung, Kwang Pyo Kim · 2026
Read Dulaglutide versus empagliflozin as add-on therapy to metformin and sulfonylurea in type 2 diabetes: a randomized pilot study with exploratory metabolomic and microbiome analyses by Ji Eun Jun, Da-Hee Oh, In-Kyung Jeong, Hyun Jin Ryu, You-Cheol Hwang, Kyu Jeung Ahn, Ho Yeon Chung, Kwang Pyo Kim (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13318618.txt.
Description
Ji Eun Jun and co-authors report a 2026 randomised pilot study comparing two add-on drugs for type 2 diabetes that stayed uncontrolled on metformin and a sulfonylurea: weekly dulaglutide or daily empagliflozin. The main phase ran twelve weeks, with observation out to week 36.
Twenty-four patients finished the main phase, thirteen on dulaglutide and eleven on empagliflozin. Both drugs lowered the blood sugar marker HbA1c by week 12, with no clear gap between them. Empagliflozin cut insulin resistance and brought earlier weight and fat loss, while dulaglutide raised a marker of insulin-producing cell function and lost weight more gradually. Blood metabolite and gut microbe checks hinted at modest differing patterns worth testing in bigger studies.
Catalog record
| CREATOR | Ji Eun Jun, Da-Hee Oh, In-Kyung Jeong, Hyun Jin Ryu, You-Cheol Hwang, Kyu Jeung Ahn, Ho Yeon Chung, Kwang Pyo Kim |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42059 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |